Dubai Summit: AI and New Drugs Forge GCC's Strategy Against IBD

DUBAI, UAE – July 21, 2026 – The inauguration of the IBD Summit 2026 in Dubai signals a critical inflection point for healthcare strategy in the Gulf. Opened by H.E. Mubaraka Ibrahim, the dual Chief Information Officer and Chief AI Officer at Emirates Health Services (EHS), the summit convenes a powerful coalition of medical experts, policymakers, and industry titans. Hosted by Johnson & Johnson, this gathering is not a typical medical conference; it is the strategic frontline in a burgeoning war against a chronic disease that has seen an explosive rise across the Gulf Cooperation Council (GCC).

Under the theme "The IL-23 era for IBD: UAE Experience Exchange," the summit tackles Inflammatory Bowel Disease (IBD) by uniting two powerful forces: breakthrough biologic drugs and the transformative potential of artificial intelligence. As H.E. Mubaraka Ibrahim articulated in her opening, success hinges on the tight integration of medical expertise with emerging technologies and the expansion of strategic partnerships. For the GCC, a region grappling with the health consequences of rapid modernization, this summit represents a deliberate move to build a resilient, technology-forward defense against a significant public health threat.

The Rising Tide: IBD as a Strategic Regional Challenge

The urgency underpinning the IBD Summit is rooted in stark epidemiological data. Once considered a predominantly Western ailment, IBD—encompassing Crohn's disease and ulcerative colitis—is now a rapidly growing health crisis in the GCC. Research highlights an alarming trend: since 1990, IBD prevalence in the UAE and Qatar has skyrocketed by 898% and 967%, respectively. Projections suggest these rates could climb to nearly 60 per 100,000 people by 2030, placing immense strain on healthcare systems.

This surge is more than a statistic; it represents a significant humanistic and economic burden. The 'Westernization' of lifestyles, characterized by diets high in processed foods and more sedentary habits, is a primary suspect. The cost of this shift is steep. Direct annual costs for treating a single patient with Crohn's disease can reach as high as $34,000 in the region, compounded by indirect costs from lost productivity. For nations heavily invested in building human capital, a chronic condition that strikes individuals in their prime productive years is a direct threat to long-term economic stability. The UAE's 2025 IBD consensus guidance, which incorporates new therapies, underscores a proactive national effort to standardize care and mitigate this growing challenge.

The IL-23 Era: A New Pharmaceutical Arsenal

Central to the summit's theme is the dawn of the "IL-23 era." This refers to a new class of highly targeted biologic drugs that are revolutionizing IBD treatment. Interleukin-23 (IL-23) is a cytokine that plays a key role in the inflammatory cascade driving IBD. By selectively inhibiting this pathway, new therapies offer the potential for greater efficacy and a more favorable safety profile compared to older, broader-acting immunosuppressants.

Johnson & Johnson, the summit's host, is a key player in this field. Its pharmaceutical arm, Janssen, has developed TREMFYA® (guselkumab), the first and only selective IL-23 inhibitor approved for both ulcerative colitis and Crohn's disease that offers a fully subcutaneous regimen for both induction and maintenance. This innovation not only represents a scientific advance but also a significant improvement in patient quality of life, moving treatment out of infusion centers and into the home. This drug, along with the established IL-12/23 inhibitor STELARA® and a promising pipeline that includes dual-pathway antibodies, forms the backbone of the company's strategic commitment to immunology.

"The IBD Summit 2026 serves as an important platform for scientific exchange and regional collaboration, helping us advance innovation and improve outcomes for patients living with inflammatory bowel disease," said Pedro Matos-Rosa, General Manager of Janssen/J&J Gulf. His statement reflects a broader corporate strategy that intertwines pharmaceutical development with regional partnerships, such as collaborations with the UAE IBD Society and the Saudi Gastroenterology Association, to build a comprehensive ecosystem of care.

AI and Digital Twins: The UAE's Technological Force Multiplier

If advanced pharmaceuticals represent the new arsenal, then artificial intelligence is the command-and-control system being built to deploy it effectively. H.E. Mubaraka Ibrahim's leadership at Emirates Health Services exemplifies the UAE's national strategy of leveraging technology as a force multiplier in public services. EHS is aggressively moving beyond reactive treatment towards a model of prediction, prevention, and precision medicine.

This is not theoretical. EHS has already launched "Amal," the UAE's first AI Physician Assistant, which conducts conversational medical interviews to streamline patient intake and reduce clinician burnout. Its "Care AI" project uses computer vision to monitor patient behavior and assist with diagnostics, while a "Digital Twin" project at Al Qassimi Hospital, developed with Schneider Electric and Microsoft, is optimizing energy use and reducing the facility's carbon footprint. These initiatives demonstrate a holistic vision where AI enhances operational efficiency, improves patient outcomes, and drives sustainability. H.E. Mubaraka Ibrahim’s emphasis on integrating medical expertise with such technologies is a blueprint for how healthcare systems can manage escalating complexity and cost.

Forging a Collaborative Ecosystem of Care

The true strategic value of the IBD Summit 2026 lies in its function as a nexus for collaboration. The event, professionally orchestrated by the experienced medical event organizer Meeting Minds Experts, is designed to break down silos. Initiatives launched and celebrated here—like the GCC IBD Patient Conversation Guide and the symbolic IBD Remission Pledge Wall—are tangible outputs of this collaborative spirit.

Critically, the summit also recognized the vital role of specialized nursing in managing this complex chronic disease. The acknowledgment of Ms. Nadine Omar, a trainer for the first ECCO IBD Nursing Certification Program in the region, highlights a crucial component of the multidisciplinary care team. IBD nurses are indispensable for patient education, monitoring treatment adherence, and providing psychosocial support—functions that are essential for achieving long-term remission and improving quality of life. By championing this specialized training, the region is investing in the human infrastructure necessary to support its technological and pharmaceutical advancements. This fusion of high-tech innovation, cutting-edge science, and dedicated human expertise is what will ultimately determine success in the fight against IBD.